G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis
Biochemical Pharmacology · 2024
DOI: 10.1016/j.bcp.2024.116077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Guoyang Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Techn…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Ferroptosis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tianjin Municipal Science and Technology Program.
Abstract (Originalsprache)
Compound G-4 is a derivate of cyclin-dependent kinase inhibitor Rocovitine and showed strong sensitivity to triple negative breast cancer (TNBC) cells. In this study, the antitumor activity, mechanism and possible targets of G-4 in TNBC were investigated. Flow cytometry and immunoblotting showed that G-4 not only arrested the S phase of the cell cycle, but also induced apoptosis in TNBC cells via the mitochondrial pathway through inhibiting epidermal growth factor receptor (EGFR), AKT and MAPK pathways. In addition, G-4 induced the iron-mutagenesis process in TNBC cells and down-regulated differentially expressed gene lipid carrier protein 2 (LCN2) by RNA-seq. Moreover, G-4 elevated levels of cytosolic reactive oxygen species (ROS), lipid ROS, Fe and malondialdehyde (MDA), but decreased levels of superoxide dismutase (SOD) and glutathione (GSH), consistent with the effects of iron-mutagenic agonists Erastin and RSL3, which were inhibited by the iron inhibitor ferrostatin-1 (Fer-1). Furthermore, a LCN2 knockdown cell model was established by siRNA transfection, the IC50 of G-4 was increased nearly 100-fold, accompanied by a trend of no ferroptosis characteristic index. The results indicated that G-4 suppressed the malignant phenotype of TNBC, induced apoptosis by inhibiting EGFR pathway and promoted LCN2-dependent ferroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Technology, Tianjin 300457, China.
- Sorbonne Université, Institut Parisien de Chimie Moléculaire, UMR8232 CNRS, 4 place Jussieu, 75005 Paris, France.
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Technology, Tianjin 300457, China; Université Paris Cité, 4, avenue de l'Ob…
- China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Technology, Tianjin 300457, China. Electronic address: tyo201485@tust.edu.c…
Förderung
- National Natural Science Foundation of China
- Tianjin Municipal Science and Technology Program
Zitieren
APA
Sun, G., Wang, J., Liu, F., Zhao, C., Cui, S., Wang, Z., Liu, Z., Zhang, Q., Xiang, C., Zhang, Y., Galons, H., Yu, P., & Teng, Y. (2024). G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116077
Vancouver
Sun G, Wang J, Liu F, Zhao C, Cui S, Wang Z, et al. G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116077
BibTeX
@article{Sun2024,
author = {Sun, Guoyang and Wang, Jinjin and Liu, Futao and Zhao, Cai and Cui, Shanshan and Wang, Zhaoyang and Liu, Zhen and Zhang, Qian and Xiang, Cen and Zhang, Yongmin and Galons, Herve and Yu, Peng and Teng, Yuou},
title = {G-4 inhibits triple negative breast cancer by inducing cell apoptosis and promoting LCN2-dependent ferroptosis},
journal = {Biochemical Pharmacology},
year = {2024},
doi = {10.1016/j.bcp.2024.116077}
}
EUVIMED